BİLİCİ, A. Et Al. 1. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study. Acta Oncologica , vol.62, no.4 , 381-390.

BİLİCİ, A., ÖLMEZ, Ö. F., Kaplan, M. A., Oksuzoglu, B., Sezer, A., Karadurmus, N., ... ÇUBUKÇU, E.(1). Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study. Acta Oncologica , vol.62, no.4, 381-390.

BİLİCİ, Ahmet Et Al. "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study," Acta Oncologica , vol.62, no.4, 381-390, 1

BİLİCİ, Ahmet Et Al. "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study." Acta Oncologica , vol.62, no.4, pp.381-390, 1

BİLİCİ, A. Et Al. (1) . "Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study." Acta Oncologica , vol.62, no.4, pp.381-390.

@article{article, author={Ahmet BİLİCİ Et Al. }, title={Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study}, journal={Acta Oncologica}, year=1, pages={381-390} }